 |
|
|
| |
Chronic HCV Infection: How Does Maturation of the
HCV Infected Patient Population Impact Drug Development - Gary Davis MD
|
| |
| |
Gary L Davis, M.D.
Director, General and Transplant Hepatology
Baylor University Medical Center
Dallas, TX
Reported by Jules Levin
The 5th International Workshop on Clinical Pharmacology of Hepatitis Therapy
Boston, MA June 23-24, 2010
|
| |
|
|
|
|
|
